Pangea Biomed Joins Second Phase of LiquidBX Consortium to Improve Cancer Detection and Treatment Response Prediction

Pangea Biomed, the startup behind the advanced cancer response prediction platform ENLIGHT, today announced its participation in the next phase of the LiquidBX consortium.